On 9 September 2022 the US FDA approved Bristol Myers Squibb’s first-in-class tyrosine kinase 2 (TYK2) inhibitor Sotyktu (deucravacitinib) for the treatment of moderate-to-severe plaque psoriasis in adults, making it the first selective TYK2 inhibitor to be approved for any indication. We expect this news to have a positive read-across for Sareum Holdings’ lead asset, SDC-1801, a dual TYK2/JAK 1 inhibitor. As a reminder, Sareum recently announced the filing of a clinical trial authorisation appl ....
13 Sep 2022
Sareum Holdings - Sotyktu approval positive read-across for SDC-1801
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Sareum Holdings - Sotyktu approval positive read-across for SDC-1801
Sareum Holdings plc (SAR:LON) | 26.8 1.7 30.5% | Mkt Cap: 26.4m
- Published:
13 Sep 2022 -
Author:
Soo Romanoff -
Pages:
2
On 9 September 2022 the US FDA approved Bristol Myers Squibb’s first-in-class tyrosine kinase 2 (TYK2) inhibitor Sotyktu (deucravacitinib) for the treatment of moderate-to-severe plaque psoriasis in adults, making it the first selective TYK2 inhibitor to be approved for any indication. We expect this news to have a positive read-across for Sareum Holdings’ lead asset, SDC-1801, a dual TYK2/JAK 1 inhibitor. As a reminder, Sareum recently announced the filing of a clinical trial authorisation appl ....